StockData

VitaNova Life Sciences Corp (VNOV) stock analysis

VNOVOTCWholesale-Apparel, Piece Goods & NotionsFiscal year ends April 30
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026Score 8/30
$4.50+0.50 (+12.50%)

Close on Oct 19, 2026Market cap $37.52MP/E –Yield –

StockData Score

Prices as of Nov 13, 2026How the score works

Value0Growth2Performance1Health5Dividend0

Weak8 of 30 checks passed

VitaNova Life Sciences passes 8 of the 30 checks behind our score; 17 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
2/6
Past performance
1/6
Financial health
5/6
Dividend
0/6

What stands out

  • No debt

    VitaNova Life Sciences has no borrowings on its latest balance sheet.

  • Revenue growing 10%+ a year

    Revenue grew 330% a year over the last three fiscal years.

  • Interest well covered

    No meaningful interest expense to cover.

  • Debt covered by cash flow

    There is no debt to cover.

What to watch

  • Return on capital under 10%

    Return on invested capital was -11.9%, below the 10% that usually covers the cost of capital.

  • Gross margin slipping

    Gross margin was 26.9% over the last twelve months, against 59.1% a year earlier.

  • Net margin below its 5-year average

    Net margin was -3.5% over the last twelve months, against a 5-year average of 21.6%.

  • Net margin below the industry

    VitaNova Life Sciences's net margin of -3.5% is below the Wholesale Trade-non-durable Goods median of -0.1%.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth2/6

  • Revenue growing 10%+ a year

    Revenue grew 330% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 22.0% over the last twelve months; the Wholesale Trade-non-durable Goods median is 3.8%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin slipping

    Gross margin was 26.9% over the last twelve months, against 59.1% a year earlier.

Past performance1/6

  • Return on equity

    Needs positive equity and five years of results.

  • Return on capital under 10%

    Return on invested capital was -11.9%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    VitaNova Life Sciences's return on equity of -6.0% is above the Wholesale Trade-non-durable Goods median of -6.5%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin below its 5-year average

    Net margin was -3.5% over the last twelve months, against a 5-year average of 21.6%.

  • Net margin below the industry

    VitaNova Life Sciences's net margin of -3.5% is below the Wholesale Trade-non-durable Goods median of -0.1%.

Financial health5/6

  • No debt

    VitaNova Life Sciences has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    No meaningful interest expense to cover.

  • Short-term assets cover short-term debts

    Current assets are 7.13 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6

  • No dividend

    VitaNova Life Sciences has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for VitaNova Life Sciences. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Wholesale Trade-non-durable Goods median 22.6

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Margins

Share of revenue, fiscal years 2017 to 2026

Gross margin

30.1%

Operating margin

0.1%

Net margin

-1.2%

See a number that looks wrong?